文献速递肺结节与肺癌

评估国家肺癌筛查试验的普遍性:I期疾病患者比较

Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

本研究比较NLST与SEER-Medicare中65-74岁I期非小细胞肺癌患者,发现符合NLST标准的老年手术患者术后30/60/90天死亡率无差异,5年肺癌特异性生存相似,但NLST全因死亡更低;未手术者结局差。

要点

  • 符合NLST标准的老年I期肺癌手术患者术后死亡率与NLST无差异。
  • NLST组全因死亡风险更低(HR 0.71),但肺癌特异性生存相似。
  • 未手术的早期患者治疗死亡率高,合并症多者筛查获益可能有限。

核心结论

  • 符合NLST入组标准且接受手术的老年I期肺癌患者术后结局良好,肺癌特异性5年生存与NLST相似。
  • 合并症显著或未手术者竞争性死亡风险可能削弱筛查获益,无证据推荐该组筛查。

研究设计与样本

  • 比较NLST与SEER-Medicare数据库中65-74岁I期非小细胞肺癌患者结局的分析性研究。

主要发现

  • SEER-Medicare NLST合格队列与NLST手术组相比,30、60、90天手术死亡调整比值比无差异(P值分别为0.97、0.65、0.46)。
  • 5年肺癌特异性生存两组无差异(HR 0.84,NLST vs. SEER-Medicare NLST合格队列;P=0.21)。
  • 全因死亡调整HR在NLST组更优(HR 0.71;P<0.01)。
  • 未接受手术的早期患者30、60、90天治疗死亡率分别为13.1%、18.9%、23.9%。

临床怎么用

  • 对符合NLST标准的老年I期肺癌患者,手术预后良好,筛查获益可外推。
  • 合并症多或无法手术者,筛查获益可能被竞争性死亡削弱,不推荐筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: The findings of the NLST (National Lung Screening Trial) are the basis for screening high-risk individuals according to age and smoking history. Although screening is covered for eligible Medicare beneficiaries, the generalizability of the NLST in the elderly population has been questioned. OBJECTIVES: Compare outcomes of patients diagnosed with stage 1 non-small cell lung cancer in the NLST to a nationally representative cohort of elderly patients Methods: Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare and NLST datasets for patients with stage 1 disease aged 65 to 74 years. MEASUREMENTS AND MAIN RESULTS: Lung cancer-specific mortality, all-cause mortality, and 30-, 60-, and 90-day treatment mortality were measured. When compared with the NLST group undergoing surgery for stage 1 non-small cell lung cancer, those in the SEER-Medicare NLST eligible cohort had no difference in adjusted odds ratios for 30-, 60-, and 90-day surgical mortality (P values = 0.97, 0.65, and 0.46, respectively). Although the 5-year cancer-specific survival did not differ between cohorts (hazard ratio [HR], 0.84 NLST vs. SEER-Medicare NLST eligible; P = 0.21), the adjusted HR estimate for all-cause mortality was better in the NLST cohort (HR, 0.71; P < 0.01). For patients who did not receive surgery for early-stage disease (presumably for curative intent), the outcomes were far worse (13.1, 18.9, 23.9%, for 30-, 60-, and 90-day treatment mortality, respectively). CONCLUSIONS: Elderly patients with minimal comorbid conditions meeting the inclusion criteria of the NLST who underwent surgery had excellent postoperative outcomes and similar lung cancer-specific 5-year survivorship. In those with significant comorbidities or those not undergoing surgery, competing causes of death may diminish the benefit, and there is no evidence to recommend screening in this group.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Tanner NT, Dai L, Bade BC, et al. Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease. Am J Respir Crit Care Med. 2017. PMID: 28722466. doi:10.1164/rccm.201705-0914OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。